What are the contraindications for Mobic (meloxicam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Contraindications for Mobic (Meloxicam)

Mobic (meloxicam) is contraindicated in patients with known hypersensitivity to meloxicam, history of aspirin or NSAID-induced asthma, urticaria, or allergic-type reactions, and in patients with severe hepatic or renal impairment. 1

Absolute Contraindications

  • Known hypersensitivity to meloxicam or other components of the formulation 1
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs 1
  • Active peptic ulcer disease 1
  • Severe hepatic failure 1
  • Severe renal impairment 1
  • Third trimester of pregnancy 1
  • History of NSAID-induced Stevens-Johnson syndrome or toxic epidermal necrolysis 1

Relative Contraindications/Use with Caution

Cardiovascular Conditions

  • Heart failure with reduced ejection fraction (HFrEF) 1
  • Hypertension 1
  • History of myocardial infarction 1
  • Increased risk of cardiovascular events 1

Gastrointestinal Conditions

  • History of gastrointestinal bleeding or ulceration 1
  • Helicobacter pylori infection 1
  • Concomitant use of corticosteroids or selective serotonin reuptake inhibitors (SSRIs) 1

Other Conditions

  • Elderly patients (>65 years) - increased risk of adverse effects 1
  • Patients with chronic alcohol abuse 1
  • Concomitant use of anticoagulants - increased bleeding risk 1
  • Mastocytosis - may trigger mast cell degranulation 1
  • Renal impairment - may worsen kidney function 1
  • Hepatic insufficiency 1

Special Populations

Elderly Patients

  • Use with extreme caution in patients >75 years due to significantly increased risk of gastrointestinal bleeding (risk increases from 1 in 2,100 in adults <45 years to 1 in 110 in adults >75 years) 1
  • Lower doses should be considered 1

Patients with Asthma

  • Meloxicam should be avoided in patients with aspirin-exacerbated respiratory disease (AERD) 1
  • However, as a preferentially selective COX-2 inhibitor, meloxicam may be better tolerated than non-selective NSAIDs in some patients with NSAID sensitivity 1, 2

Drug Interactions

  • Avoid concomitant use with other NSAIDs including aspirin 1
  • Use caution with anticoagulants due to increased bleeding risk 1
  • Potential interaction with drugs that prolong QT interval 1
  • May reduce effectiveness of antihypertensive medications 1
  • May increase risk of methotrexate toxicity 1

Monitoring Recommendations

  • Regular assessment for gastrointestinal and renal toxicity 1
  • Monitor for hypertension and signs of heart failure 1
  • Monitor liver function tests in long-term use 1
  • Assess for drug-drug and drug-disease interactions 1

Clinical Pearls

  • Although meloxicam is a preferentially selective COX-2 inhibitor, it is not as selective as celecoxib and still carries risks associated with NSAIDs 1, 3
  • In patients with NSAID hypersensitivity manifested as urticaria/angioedema, meloxicam may be better tolerated than other NSAIDs, with studies showing only 1.1% cross-reactivity 2
  • Patients requiring meloxicam who have a history of gastrointestinal risk factors should receive concomitant gastroprotection with a proton pump inhibitor or misoprostol 1
  • Meloxicam belongs to the oxicam class of NSAIDs, which has been associated with higher risk of severe cutaneous adverse reactions compared to other NSAID classes 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000

Research

Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug.

Expert opinion on investigational drugs, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.